Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

BACKGROUND: Stimulation of 4-1BB with agonistic antibodies is a promising strategy for improving the therapeutic efficacy of immune checkpoint inhibitors (ICIs) or for overcoming resistance to ICIs. However, dose-dependent hepatotoxicity was observed in clinical trials with monoclonal anti-4-1BB ago...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Seongju, Park, Eunyoung, Kim, Hyung-Don, Sung, Eunsil, Kim, Hyunjoo, Jeon, Jaehyoung, Kim, Youngkwang, Jung, Ui-jung, Son, Yong-Gyu, Hong, Youngeun, Lee, Hanbyul, Lee, Shinai, Lim, Yangmi, Won, Jonghwa, Jeon, Minwoo, Hwang, Shin, Fang, Lei, Jiang, Wenqing, Wang, Zhengyi, Shin, Eui-Cheol, Park, Su-Hyung, Jung, Jaeho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261887/
https://www.ncbi.nlm.nih.gov/pubmed/34230109
http://dx.doi.org/10.1136/jitc-2021-002428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261887/
https://www.ncbi.nlm.nih.gov/pubmed/34230109
http://dx.doi.org/10.1136/jitc-2021-002428

Ejemplares similares